Magnetar Financial LLC acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) in the first quarter, Holdings Channel reports. The firm acquired 149,489 shares of the company’s stock, valued at approximately $1,576,000.
Other large investors have also added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in Roivant Sciences during the fourth quarter valued at $36,000. Allspring Global Investments Holdings LLC raised its stake in shares of Roivant Sciences by 42.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock worth $60,000 after purchasing an additional 1,608 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Roivant Sciences in the first quarter worth $72,000. Premier Path Wealth Partners LLC purchased a new position in shares of Roivant Sciences in the first quarter worth $126,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Roivant Sciences in the fourth quarter worth $170,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.
Roivant Sciences Stock Performance
NASDAQ:ROIV traded up $0.06 during mid-day trading on Friday, hitting $10.80. 3,579,769 shares of the company traded hands, compared to its average volume of 4,771,108. The stock’s fifty day moving average price is $10.86 and its 200-day moving average price is $10.88. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.24. The company has a quick ratio of 25.24, a current ratio of 25.24 and a debt-to-equity ratio of 0.07. The firm has a market cap of $7.98 billion, a price-to-earnings ratio of 2.13 and a beta of 1.24.
Analysts Set New Price Targets
Several research firms have recently weighed in on ROIV. The Goldman Sachs Group boosted their price target on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Piper Sandler boosted their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft boosted their price target on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Friday, May 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Tuesday, June 18th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average price target of $17.10.
Read Our Latest Stock Analysis on Roivant Sciences
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
- Five stocks we like better than Roivant Sciences
- How to Find Undervalued Stocks
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What is the NASDAQ Stock Exchange?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.